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To determine whether platelel •nctivating factor is a specific me.
diaor of cyclic flow variations in damaged stenotic arteries and
whether it contributes In eoocctusion after thrambclysiy femoral
arteries in anesthetized dogs were . subjected to mural Injury and
l
::gh grade stenosis to induce cyclic flow variations (21 ! 4.mt
or methods selected to elicit
platelet-Arts
and fibrin-rids throes'
bests,
Oral administration of a novel triazolohenzodiaaeptne
(L'46,195 110 mg/kg]) that selcetivdy inhibits platelet-actlvatissg
factor abolished cyclic flow variations within 120 min and for a2 h
thereafter compared with persistent flow ,ariason  in dogs given
saline solution . Platelet aggregation induced ex vim with platelet .
activating factor was inhibited in parallel wish in vivo Inhibition of
cyclic flow variations alter adm ;
. istration of V46,195
. However,
boreal ma-son bleeding time was not affected.
It is generally accepted
(1-4)
that Bctirratiot, of platelets
leading to their adherence and aggregation at a site of
ruptured atnerosderotic plaque or other vessel injury con-
trihates to the initiation of coronary artery thrombosis, with
sequelae including unstable angina pectoris
. myocardial in-
farction and recurrent infarction elicited by vessel reocclu-
sion after successful thrombolysis . Although a number of
mediators
of platelet activation have been identified . specific
mediators expressed in response to vessel damage remain
unknown.
One patential mediator is platelet-activating factor, a
phospholipid produced and released from stimulated endo-
thelial coils . neutrophils and platelets that participates in
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After thrombosis, administration of U46,195 before thrombob
ysis was induced with human recc
;abhiaat
:sac.--ype plasmino-
gen activator (1 .7 mglkg intravenously over 60 min) prevented
reocclusion within 120 min in six of eight and six of seven arteries
by platelet-rich and fibrin-rich thrombosis, respectively- In con.
trast, in dogs given saline solution, reocdusion occurred in eight of
eight (p = 0 .007 compared with U46,195) and five of eight arteries
by platelet-rieh and fibrin-nlch thrombosis, respectively .
Thus, both cyclic flow variations and reoccluslon after throm-
holysis appear to be mediated in part by platelet-activating factor .
The results suggest that inhibition of platekbaetivating factor
with specific antagonists may be useful in reducing platelet-
mediated oedusion of coronary arteries without eliciting bleeding .
O Am Call Cordial 1991
;18:1804-10)
inflammatory reactions and is one of the most potent activa-
tors of platelets known (5-7) . Elucidation of the role of
platelet-activating factor in thrombosis has been facilitated
by recognition that triazolobenzodiazepines such as alprazo-
lam and triazolam (important clinically for their anxiolytic
and hypnotic properties) selectively antagonize platelet ag-
gregation induced in vitro with platelet-activating factor (8) .
We have shown (9) that these compounds (but not benzodi-
azepines that lack a triazole ring) markedly inhibit in vivo
cyclic flow variations attributable to intermittent accumula-
tion and dislodgment of platelets in damaged stenotic coro-
nary arteries of dogs (10)- Thus, platelet-activating factor
might be a mediator of platelet-dependent cyclic flow varia-
tions in experimental animals that are analogous to episodic
occlusions producing angina pectoris in patients with coro-
nary artery disease (11) .
Platelet-activating factor may also contribute to reocdu-
sion of coronary arteries after initially successful thrombol-
ysis, which occurs in approximately 20% of patients (12) .
Reocclusion is not prevented by conventional agents, includ-
ing
aspirin and heparin (13,14). In experimental animals,
although aspirin has been shown to attenuate cyclic flow
variations 1!0), we have demonstrated (15) that it reduces
0775-1097191157.50
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reocclusion after coronary thrombolysis by only 50%
. Hep-
arin is even less effective .
The present
sandy
was designed to determine u'hethor
1) antagonism of platelet-activating factor with a novel
lriazolobenzodiazepine, U46,195, devoid of central nervous
system activity compared with triazolam, reduces cyclic
flow variations in stenotic femoral arteries in dogs ; and 2)
antagonism of platelet-activating factor with U46,195 re-
duces or prevents thrombotic reocclusion after thrombolysis
in dogs . To assess the role of platelet-activating factor in
arterial reocclusion, we simultaneously utilized in the same
animal two disparate femoral artery thrombosis preparations
(16) designed to invoke different amounts of platelet activa-
tion
. In one preparation, electrical injury of the arterial wall
was used to elicit an intense platelet response . yielding
platelet-rich thrombosis ; in the other, insertion of a coil of
copper wire into the arterial lumen was used to induce
fibrin-rich thrombosis with less platelet activation . We have
shown (16) that a high dose of aspirin (30 mg/kg body weight)
abolishes reocclusion by platelet-rich but not fibrin-rich
thrombosis in these preparations.
Methods
Animal preparations . All procedures conformed with the
"Position of the American Heart Association on Research
Animal Use" (November 11, 1984) and were approved by
the Animal Studies Committee at Washington University .
Forty-three mongrel dogs weighing 7 to 14 kg were anesthe-
tized with sodium pentonarbital (30 mglkg intravenously)
after an overnight fast. The trachea was intubated and the
lungs were ventilated with room air supplemented with
oxygen . The pH of venous blood was maintained at 7 .38 to
7 .42 by adjusting the ventilation rate . The external jugular
veins were catheterized for withdrawal of blood samples and
administration of agents . Catheter potency was maintained
by slow infusions of saline solution (0.9%). An orogastric
tube composed of 0.25-in . (0.635 cm) tygon tubing was
passed into the stomach and its position verified by aspira-
tion of stomach contents .
Experimental Protocols
Cyclic flow studies . To assess the effect of platelet-
activating factor on cyclic flow variations, the left femoral
artery in 22 dogs was exposed and a Doppler probe was
placed around the vessel to measure flow velocity
. The
vessel was damaged at a site between the Doppler flow probe
and the saphenous branch by clamping 10 rimes with a
hemostatic forceps. A band of lygon tubing, 3 to 4 mm in
length, was then placed around the damaged segment . The
band was constricted ur.til the hyperemic flow response to a
20-s occlusion of the femoral artery was abolished . The
stenosis was fixed by suturing the edges of the hand to .
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gerber . Cyclic flow variations characterized by an abrupt
change in average blood flow velocity >5%c (from nadir to
peak) and with a regular frequency >15/h typically began
spontaneously within I h ofthe induction of stenosis . Cyclic
flow variations were recorded for an additional 30 min before
oral administration of either triazolam (10 .20 and ?0
mg/kg)
or U46 .195 110 mg/kg) prepared as a slurry in 11 .9% saline
solution (35 mill or an equivalent volume of saline solution as
a control . The incidence of cyclic flow variations was
recorded for -4 h after treatment .
Reocclusion studies, To assess the effect of antagonism of
platelet-activating factor on arterial reocclusion after
thrombolysis
. both femorai arteries in 21 dogs were exposed .
small branches ligated and loose connective tissue -emoved
.
Doppler flow probes were placed proximaily around each
vessel. Thrombosis was induced in one femoral artery by
applying anodal current through a transluminal electrode
.
resulting in vascular injury, and in the coniralateral artery by
implantation of a coil of thrombogenic copper wire as
described previously (16) . Briefly, for thrombosis induced
electrically . a 22 _gauge needle electrode was inserted
obliquely into the Iselen of one artery distal to the Doppler
probe and st . /!tined with sutures through extravascular
tissue on either tie of the vessel . Electrical stimulation was
initiated by connecting the electrode in series with the
positive terminal of a 9-V battery, an ammeter and a 50 lea
potentiometer, A ground wire was sutured to the
subcuta-
neous tissue to complete the circuit . Current (300 AA) was
applied to the electrode until complete thromhotic occlusion
had occurred, verified as zero few velocity on the Doppler
flow tracing . Before occlusion of this vessel was complete,
the sharpened end of a coil of copper wire was pushed
through the wall :
f the contralateral femoral artery distal to
the Doppler probe and rotated until approximately three
complete turns of the coil were within the lumen. Because
thrombosis occurs more rapidly after implantation of a
copper coil compared with electrical injury, delayed place-
ment of the coil produced comparable intervals for both
vessels between the onset of complete occlusion and admin-
istration of the antagonist .
Fifteen minutes after bilateral thrombotic occlusions,
either U46 .195 (t0 mg/kg, n = 11) in 0 .9%0 saline solution (35
ml) or an equivalent volume of saline solution as a control
In = 101 was administered orally. Fifteen minutes later,
human recombinant tissue-type plasminogen activator
trt-PA jActivase], Genentech) was infused intravenously at a
total dose of 1 .7 mg/kg over 60 min, with 12% of the dose
given as a bolus infusion initially . Flow velocity in both
vessels was monitored for 2 h after the end of the infusion of
rt-PA. Times of onset of initial thrombotic occlusion . suc-
cessful recanaization defined prospectively as a return of
average flow velocity to >50% of the baseline value and
reocclusion if it occurred were recorded for each vessel .
Average flow velocity at the end of the observation interval
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was expressed as a percent of the flow at baseline (before
thrombosis) .
Henmatologic
Studies
Aggregation of platelets
. This was characterized in plate-
let-rich plasma obtained before and at hourly intervals after
administration of the antagonists of platelet-activading factor
in cyclic flow variation studies and before and 90 min after
administration of rt-PA in reocclusion studies . Venous blood
was withdrawn into a syringe containing one part 3 .8%
sodium citrate to nine parts blood, Platelet-rich plasma was
obtained by centrifugation at 70 g for 10 min
. Platelet-poor
plasma was obtained by recentrifugation of the remaining
sample at 1,500 g for 10 min, The platelet carat in platelet-
rich plasma was adjusted to a final concentration of 2 .5 x
10'/mm' with autologous platelet-poor plasma. Aggregation
of the count-adjusted platelet-rich plasma was measured
turbidimetrically with an aggregometer (Payton Associates)
and with the use of platelet-activating factor (Sigma Chem-
ical Co .) dissolved in 0.9% saline solution and bovine tendon
collagen (Helena Laboratories) as the agonists
. Under base-
line conditions, the minimal threshold concentration of ago-
nists resulting in a >50% increase in light transmission was
determined with reference to that of platelet-poor plasma
representing 100% transmission . Final concentrations of
platelet-activating factor ranging from 9 to 180 nM and of
collagen ranging from 1 .25 to 10 9ag/ml were employed
. The
response to the same threshold concentration of agonists
was defined it : subsequent samples
.
Buccal muensa bleeding and clotting times . Bleeding times
were assessed before and 2 h after administration of antag-
onists of platelet-activating factor in cyclic flow studies with
the use of a Simplate II device (Organon Teknika) and the
method of Jergens et al . (17). Prothrombin time and acti-
vated partial thromboplastin time were assessed in blood
samples collected before and 90 min after the end of the
infusion of rt-PA in reocclusion studies with use of a
Coag-A-Mate XC automated coagulation timer (Organon
Teknika) .
Statistics . Results are expressed as mean values ± SD .
Fisher's exact test was used to compare the incidence of
reocclusion in dogs given the antagonist of platelet-
activating factor or saline solution . Differences between
groups for all other variables were compared by multiple
analysis of variance . A p value <_ 0.05 was considered
significant .
Results
Effect of antagonism of platelet-activating factor on cyclic
flow variations. Induction of mural vessel injury and high
grade stenosis in the femoral artery resulted in cyclic flow
variations in each of 22 dogs . The frequency of cyclic flow
variations averaged 28 ± 4111 . Administration of the higher
doses of triazolam inhibited cyclic flow variations com-
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Figure 1
. Inhibition of cyclic flow variations after administration of
saline solution or different doses of antagonists of platelet-activating
factor
. Data points are mean'- SD of values calculated from cyclic
flow variations recorded over 30-min intervals . Complete inhibition
was sustained longer with
U46.195 than with the highest dose of
triazolam.
pletely within 120 min (Fig . I)
. However, the inhibitory
effect was short-lived and cyclic flow variations began to
recur after another 60 min. In contrast, administration of
U46,195 inhibited cyclic ?sw vdriations complE .ely in four of
seven dogs within 90 min and in all seven dogs within
150 min . Furthermore, complete inhibition of cyclic flow
variations persisted for an additional 2 h (Fig. 1) .
Inhibition of platelet aggregation induced ex vivo with
platelet-activating factor paralleled inhibition of cyclic flow
variations observed in vivo after administration of U46,195
(Fig. 2). However, the threshold for platelet aggregation in
response to collagen assessed 2 h after administration of
U46,195 (3 .3 s 1 .4 pig/ml) was unchanged from the baseline
threshold (2.5 ± 0 pg/mp
. In addition, bleeding times were
unchanged from baseline values (3 .2 ± 0.2 min both before
and 2 h after antagonist), a finding consistent with the
maintenance of platelet responsiveness to other agonisls
involved in normal hemostasis .
Effects of antagonism of plateletwctivating factor on early
reocclusion. The onset of initial thrombosic occlusion and of
recanalization after administration of rt-PA occurred later in
the electrically induced injury than in the copper coil prep-
aration (Table 1) . Nevertheless, recanalization occurred
with comparable frequency in the two preparations
. The
time to recanalization, when it occurred, did not differ
between dogs given U46,195 or saline solution
.
In eight dogs given saline solution that had successful
recanalization, reocclusion occurred within I h after the end
of the infusion of rt-PA in five of eight vessels with copper
coil-induced and eight of eight vessels with electrical injury-
induced thrombosis . The incidence of reocclusion was de-
creased in dogs given U46,195, although the decrease was
significant compared with saline-treated dogs only for ves-
sels injured electrically (Table 1) . In six dogs given U46,195
• cans
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Figure 2. Concomitant e,5ects of U46.195 on cyclic flow variations
in vivo (A) and on platelet aggregation
assessed ex vivo (1111) after
femoral artery injury and stenosis in four dogs. Diminished aggre-
gation to the average threshold don (90 nIN) of platelet-activating
factor
,AT)
occurred in parallel with the reduced incidence of
cyclic now
-lotions.
in which arterial reocclusion did not occur, blood flow
velocity 2 h after the end of the infusion of rt-PA averaged
74 ± 24% of baseline flow for arteries
with copper coil-
induced and 65 ± 29 f of baseline flow for arteries with
electrical injury-induced thrombosis. In the three saline-
treated dogs with patent arteries after 2 h, blood flow
velocity averaged only 10 *-' 8% of baseline flow . When
reocclusion occurred, the time to its onset did not appear to
differ between dogs given U46,195 or saline solution.
In contrast to results in cyclic flow studies, platelet
aggregation assessed ex vivo in response
to platelet-
Table 1, Characteristics of Arterial
Occlusion, Recanalization and Reocclusion
"p = 0.007 vs . saline solution. a-PA = recombinant tissue-type
p1--cc.
activator.
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Table 2. Effect of 046
.195 on Coagulation Indexes in Seven Dogs
Rodeo 8,2 82-0.1
01 : a01cr
8' Il l IUJ x In
end of,; PA'
e
= 1,10171
Recanalizmion
Activated Portal
PrmbromhmTive
ThremhopleninTlse
tn'. :nl Iminl
Rcacciesion
'A 6m
=-,lr= Plaemiaoeen
=
.¢ ., a .pr
,[PAl loll In blood . 165 in after administration of (48 .195-
activating factor was unchanged from baseline in dogs given
046,195 . Threshold values were 100 t 40 oM In = 6) at
baseline and 130 v 40 n
.M 90 min after the end of the infusion
of rt-PA 1165 min after administration of 046,195)
. Platelet
aggregation in response to collagen was also unchanged
(threshold at baseline of 3.9 x
3 (ag/ml In = 6] and 90 min
after rl-PA of 2 .5 v 1 .8 ug/mI In = 41)- as was the bleeding
limo 11 .9 1
03 mm in = 41 at baseline and 3 0 0 .4 min at
90 min after rt-PA) . Coagulation was not affected by admin-
istration of 046.195 (Table 2) .
Effects of antagonists of platelet-activating
factor on plate-
let aggregation in vitro. Direct effects of U46,195 and 1000-
olam on platelet aggregation induced with platelet-activating
factor were assessed in platelet-rich plasma obtained from
three normal human volunteers and three dogs
not operated
on
. Because of the antagonists' insolubility in aqueous
solution, they were dissolved in 0
.2% ethanol. Ethanol
vehicle alone exhibited a slight inhibitory effect on platelet
aggregation (Fig . 3). as expected from previous studies (181 .
Addition of graded doses of the
antagonists demonstrated
that 046,195 was a more potent inhibitor of platelet
aggre-
gation than was triazolam, consistent with our results in
vivo . After taking into account the modest effect of ethanol,
aggregation of canine platelets was inhibited by 50% with
0 .024 yaM of 046,195 . whereas 50 µM11 of triazotam was
required for comparable inhibition (Fig . 3) . Similar results
were obtained with human platelets . A lower concentration
of platelet-activating factor (9 nM) was required to elicit a
submaximal response in human platelets compared with
Time cf
Tiioe of Time of
0-1 of On,,, After Onset After
Occlusion Start of e-PA End urn-PA
Prep-tot
finial Incidexe (min) incidence loin)
Copper cal
Srlins in = 91 23 0 23 819 26 0 17 98 42 0 56
(46.195 (n = 10) ') 2 20 7110 24 2U 1/7 31 In = I I
Elecrricel injury
Saline In = 101 86 0 IS 8110
U46,195 (n = 11)
107 0 67 8111
51_9 818 35032
58 a l6 218' 31 *_ 17
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Figure 3 . Representative aggregometer tracings showing aggrega-
tion of canine platelet-rich plasma in response to the addition COO
nM of platelet-activating factor (arrows) before addition of inhibitors
(CONTROL),
after the addition of 0 .2% ethanol vehicle and after
the addition of different doses of 046.195 (A) or triazolam (B)
dissolved in ethanol .
canine platelet, (90 nM), suggesting a species difference with
respect to platelet sensitivity to platelet-activating factor
.
Discussion
046,195: an inhibitor of platelet-activating factor . The
present study investigated the effect of selective inhibition of
platelet-activating factor on in vivo platelet-mediated phe-
nomena
. Oral administration of either high doses of triazo-
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lam (20 and 30 mg/kg), an agent with known hypnotic
properties shown to possess platelet-activating factor inhib-
itory properties as well (8). or a more modest dose of at novel
antagonist of platelet-activating factor, 046,195 (10 mg/kg),
that lacks central nervous system activity inhibited cyclic
flow variations at a site of
moral arterial injury and high
grade stenosis (Fig . 1). Inhibition was more rapid with
triazolam than with U46,195, but the duration of inhibition
was substantially longer with 046,195 . The onset of inhibi-
tion of cyclic flow variations in vivo coincided with inhibi-
tion of platelet aggregation assessed ex vivo with platelet-
activating factor (Fig . 2).
These results substantiate our previous supposition (9)
that platelet-activating factor is an important mediator of
cyclic flow variations in severely injured stenotic arteries
.
However, higher doses of triazolam were required to inhibit
cyclic flow variations in the femoral artery preparation
compared with those required for inhibition in the coronary
artery preparation employed previously (9).
Platelet-
activating factor also appears to play a role in arterial
reocclusion after thrombolysis, judging from the marked
reduction in the incidence of reocclusion we observed when
046,195 was administered before rt-PA (Table I) . Because
specific inhibition of platelet-activating factor was accom-
plished without compromising the ability of platelets to
respond to other agonists that may be involved in normal
hemostasis, as indicated by the lack of effect on bleeding
time, this approach may be particularly beneficial to limit
analogous platelet-mediated occlusive processes in patients
without hindrance to hemostasis . In addition, U46,195 was
shown to have no effect on coagulation variables that could
potentiate bleeding (Table 2) .
Mechanisms for cyclic flaw variations, The mechanisms
responsible for experimentally induced cyclic flow variations
are unclear, but their association with microscopic thrombi
composed mainly of platelets has been documented (10,19) .
Previous studies (19) have implicated thromboxane release
from activated platelets in the generation of cyclic flow
variations because they are attenuated by inhibition of
thromboxane synthetase . In addition, specific antagonism of
serotonin was found to attenuate cyclic flow variations (20) .
However, Apprill et al . (21) showed that infusion of platelet-
activating factor proximal to a coronary stenosis restored
cyclic flow variations despite their prior inhibition with
antagonists of either thromboxane synthetase, serotonin or
alpha, -receptors. Thus, platelet-activating factor appears to
be one of several factors that mediate experimental cyclic
flow variations .
Effect on platelet-rich versus fibrin-rich thrombi. Induc-
tion of thrombosis in both femoral arteries simultaneously by
methods that we have shown previously to result in either
fibrin-rich or platelet-rich thrombi (16) was designed to
compare the effects of inhibition of platelet-activating factor
in preparations that elicit different degrees of platelet acti-
vation. Inhibition of platelet-activating factor decreased the
incidence of reocclusion in both preparations, although the
JACC Vat, It, No.7
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reduction was significant only for vessels with electrical
injury resulting in platelet-rich thrombi (Table 1)
. .A lower
incidence of reocclusion in vessels with copper coils in
saline-treated dogs likely prevented statistical significance of
the effect of the antagonist, which can only be inferred
from
the small number of animals studied . Nevertheless, despite
differences in the ultimate composition of thrombi induced,
platelet-activating factor appeared to play a role in reocclu-
sion with either preparation . This hypothesis is consistent
with results from our previous studies (16) in which inhibi-
tion of platelet aggregation with aspirin or a specific antag-
onist of fibrinogen binding to platelet glycoprotein llblllla
receptors universally prevented reocclusion resulting from
platelet-rich thrombi, Autiplatelet agents were only partially
effective in preventing reocclusion resulting from fibrin-rich
thrombi.
In vitro studies . Although U46.195 reduced the incidence
of reocclusion, inhibition of platelet aggregation assessed ex
vivo with platelet-activating factor was not observed in these
experiments
. This finding differs from the results of our other
experiments when at comparable intervals after administra-
tion of U46,195, cyclic flow variations were abolished with
concomitant inhibition of platelet aggregation (Fig . 2) . The
discordance of these results may reflect masking of the
inhibitory effect of platelet-activating factor by the proaggre-
gatory response elicited by plasmin generated during plas-
minogen activation (22). Anticoagulation did not appear to
contribute to the observed effect
of U46,195 on reoccusirn
because neither activated partial thromboplastin time nor
prothrombin time was appreciably altered (Table 2).
In vitro studies of the effects of triazolam and U46,195 on
platelets provided evidence for specific antagonism of plate-
let-activating :actor (Fig . 3) . Human platelets appear to have
a lower threshold for activation by platelet-activating factor
than do canine platelets and consequently could require less
of the antagonist to suppress activation,
Clinical implications. It is well known (14,23) that activa-
tion and subsequent aggregation of platelets are involved in
initiation of thrombotic occlusion of coronary arteries and
reocclusion after successfLl thrombolysis . Direct inhibition
of platelet aggregation with antagonists of fibrinogen binding
to platelet glycoprotein IIb/Illa receptors may be effective .
but because this action tends to depress platelet function
profoundly or for prolonged intervals, or both, it may lead to
bleeding (24) . Inhibition of platelet activation with agents
such as recombinant desulphatohirudin that inactivate
thrombin may be even more effective and exert less pro-
found effects on hemostasis
(15) . The results of the present
study show that inhibition of platelet activation with specific
antagonists of platelet-activating factor that do not exert
concomitant effects on the central nervous system may be
useful in reducing platelet-mediated occlusion resulting from
vessel injury without compromising platelet responsiveness
to other agonises or hemostass
.
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